MediSapiens and Bayer HealthCare to Develop Platform for Managing and Analyzing Genomics Data

HELSINKI, October 11, 2011 /PRNewswire/ --

MediSapiens Ltd and Bayer HealthCare Pharmaceuticals have agreed to develop a platform for genomics data management and analysis in Oncology. The platform will enable Bayer to more effectively utilize genomics data in Oncology research, such utilization to be conducted in compliance with respective patients' informed consent and applicable laws and regulations.

"Genomics data is increasingly used both in pre-clinical and clinical research, but lacks software tools that can be adapted to various research environments. Our flexible platform and know-how in designing software for demanding bioinformatics environments will be tailored to meet the needs of Oncology research at Bayer HealthCare Pharmaceuticals.", says Tommi Pisto, CEO of MediSapiens Ltd.

"Our core knowledge is to combine bioinformatics and web software. Experience in building and managing the world's largest unified gene expression database for researchers' needs has been invaluable in creating the flexible and scalable genomics platform we now put into use for this project", adds Sami Kilpinen, PhD, CSO of MediSapiens Ltd.

About MediSapiens

MediSapiens is a bioinformatics company developing inspiring web applications for genomics researchers, pharmaceutical industry and personalized medicine. MediSapiens has unique know-how in developing software solutions for integration of both molecular and clinical data from preclinical models to interpreting comprehensive molecular profiles of individual cancer patients in clinical settings. Based on the world's largest unified gene expression database, MediSapiens platform extends into highly tailored solutions to meet the exact needs of various demanding research environments.

For more information visit http://www.medisapiens.com or email [email protected]

 

SOURCE MediSapiens Ltd.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.